ReviewWiener medizinische Wochenschrift (1946)2013
Advanced basal cell carcinoma.
Review in Wiener medizinische Wochenschrift (1946), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- A case of basal cell carcinoma of skin with bone metastasis: a case report.Journal of medical case reports · 2024Article
- Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.Open access Macedonian journal of medical sciences · 2018Review
- Very Rare Amelanotic Lentigo Maligna Melanoma with Skull Roof Invasion.Open access Macedonian journal of medical sciences · 2017Article
- Basal Cell Carcinoma Surgery: Simple Undermining Approach in Two Patients with Different Tumour Locations.Open access Macedonian journal of medical sciences · 2017Article
- Undermining plastic surgery as a possible option for treating basal cell carcinoma of the forehead.Wiener medizinische Wochenschrift (1946) · 2017Article
- Emerging concepts and recent advances in basal cell carcinoma.F1000Research · 2017Review
- Advances in the management of basal cell carcinoma.F1000prime reports · 2015Review
- Relapsing advanced metatypical basal cell carcinomas (MTBCC) of the face: surgical modalities.Wiener medizinische Wochenschrift (1946) · 2014Article
- Basal cell carcinoma of the outer nose: overview on surgical techniques and analysis of 312 patients.Journal of cutaneous and aesthetic surgery · 2014Review
- Metatypical Basal cell carcinomas: a successful surgical approach to two cases with different tumor locations.Maedica · 2014Article
- Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations.Current dermatology reports · 2014Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. Ultraviolet light exposure is the best known exogenous factor in BCC development. This is also the target for primary prevention. Advanced BCC include locally advanced tumors and metastatic tumors. Prognosis is worse compared to stage I and II BCCs. Mohs or micrographically controlled surgery is the gold standard of treatment. In patients with tumors that cannot be completely removed radiotherapy was the only alternative in the past. More recently new drugs for targeted therapy of signaling pathways like sonic hedgehog or epidermal growth factor receptor became available. More small molecules are under investigation. Since the complete response rates are limited, future research has to evaluate their combination with surgery.
Indexed as
Identifiers
23589318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.